Cancer Prehabilitation and Functional Recovery Pathways: An Evidence-Based Review

Abstract

Cancer prehabilitation and functional recovery pathways represent an evolving paradigm in oncologic care, designed to optimize patient outcomes through multidisciplinary interventions prior to treatment. This review synthesizes recent evidence on the implementation of prehabilitation programs, elucidates their mechanisms, and discusses their impact on clinical outcomes, with a focus on guideline-based recommendations and future directions for clinical practice. The article targets healthcare professionals seeking to integrate prehabilitation into comprehensive cancer management strategies.

Introduction

The management of cancer patients has traditionally focused on diagnosis, treatment, and survivorship, often overlooking the period preceding primary therapy. Cancer prehabilitation, defined as the process of enhancing a patient's functional capacity before initiation of acute treatment, has emerged as a critical opportunity to improve surgical, oncologic, and quality-of-life outcomes. Functional recovery pathways, encompassing tailored exercise, nutritional, and psychological interventions, are increasingly recognized as integral to holistic cancer care. This review aims to update clinicians on the scientific foundations, clinical relevance, and practical application of prehabilitation strategies in oncology.

Epidemiology / Disease Burden

Cancer remains a leading cause of morbidity and mortality worldwide, with over 19 million new cases and nearly 10 million deaths annually. Advances in detection and treatment have improved survival, yet a significant proportion of patients experience functional decline, treatment-related complications, and impaired quality of life. The burden is particularly pronounced among elderly individuals and those with comorbidities, who are at higher risk for poor functional outcomes. Prehabilitation offers a proactive approach to mitigate these challenges and reduce healthcare resource utilization.

Pathophysiology

The pathophysiological rationale for prehabilitation is rooted in the interplay between cancer biology, treatment-induced stressors, and the host's physiological reserve. Cancer and its therapies can precipitate systemic inflammation, catabolism, sarcopenia, and immunosuppression, culminating in reduced functional status and increased susceptibility to complications. Prehabilitation interventions aim to counteract these effects by promoting anabolism, improving cardiorespiratory fitness, and enhancing neuromuscular function, thereby strengthening resilience to treatment insults.

Risk Factors

Several patient-related and disease-specific risk factors modulate the need for, and efficacy of, cancer prehabilitation. Advanced age, frailty, comorbid conditions (such as diabetes or cardiovascular disease), poor nutritional status, baseline physical inactivity, and high tumor burden are associated with diminished functional reserve. Patients undergoing major surgery, highly toxic chemotherapy, or combined modality treatments are particularly vulnerable to functional decline and may benefit most from tailored prehabilitation pathways.

Clinical Features

Clinically, patients at risk for poor functional recovery may present with fatigue, muscle weakness, dyspnea, impaired mobility, unintentional weight loss, and psychological distress. Standardized assessment tools including the 6-minute walk test, handgrip strength, nutritional screening instruments, and patient-reported outcome measures can help identify candidates for prehabilitation and monitor progress throughout the cancer care continuum.

Diagnosis

The diagnosis of functional impairment in oncology is multifactorial, involving objective performance measures, subjective symptom assessment, and multidisciplinary evaluation. Baseline assessment should include evaluation of physical fitness, nutritional status, psychological well-being, and social support systems. Integration of these domains into risk stratification models enables individualized prehabilitation planning and facilitates shared decision-making among patients, oncologists, surgeons, and allied health professionals.

Treatment & Management

Cancer prehabilitation encompasses multimodal interventions initiated before the start of primary therapy. Core components include: (1) Exercise training, emphasizing aerobic, resistance, and flexibility modalities to enhance cardiorespiratory and musculoskeletal function; (2) Nutritional optimization, involving assessment and management of malnutrition, cachexia, and sarcopenia; (3) Psychological support, addressing anxiety, depression, and coping strategies; and (4) Education and behavior modification to promote adherence. Interventions are ideally tailored based on baseline risk and delivered via multidisciplinary collaboration. Evidence supports the feasibility and safety of prehabilitation across cancer types, particularly in surgical oncology, where it is associated with reduced postoperative complications, shorter hospital stays, and improved physical and psychological recovery.

Recent Advances / Emerging Therapies

Recent advances in cancer prehabilitation include the integration of telehealth platforms, wearable technologies for remote monitoring, and precision medicine approaches that tailor interventions to genetic, metabolic, and phenotypic profiles. Digital health innovations have enabled broader access to supervised exercise and nutritional counseling, even amid the constraints of the COVID-19 pandemic. Additionally, emerging data support the use of pharmacological agents (e.g., anabolic steroids, anti-inflammatory drugs) as adjuncts to prehabilitation in select patient populations. Ongoing clinical trials are evaluating the optimal timing, intensity, and duration of prehabilitation interventions, as well as their cost-effectiveness and impact on long-term survivorship.

Guideline Recommendations

International guidelines from organizations such as the American Society of Clinical Oncology (ASCO), European Society for Clinical Nutrition and Metabolism (ESPEN), and Enhanced Recovery After Surgery (ERAS) Society now endorse prehabilitation as a key component of comprehensive cancer care. Recommendations emphasize early assessment, multidisciplinary collaboration, individualized program design, and continuous re-evaluation throughout the treatment continuum. Guidelines highlight the importance of integrating prehabilitation into existing care pathways to optimize patient outcomes and resource utilization.

Conclusion

Cancer prehabilitation and functional recovery pathways represent a transformative approach to oncologic care, integrating evidence-based, multidisciplinary interventions to enhance patient resilience and optimize outcomes. Robust data support the clinical and economic benefits of prehabilitation in diverse cancer populations, with ongoing research poised to refine and personalize these strategies further. Adoption of guideline-driven prehabilitation programs offers a practical, mechanism-based means to address the functional challenges of cancer therapy and improve the quality of survivorship for patients worldwide.